Kazuya Shimoda

16PUBLICATIONS
58CO-AUTHORS
Medical physicsHaematological tumoursMolecular targetsCardiology (incl. cardiovascular diseases)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Mar 09, 2026
Efficacy and safety of a three-step dose escalation regimen of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a phase 3b, single-arm, multicenter study.

Tadaaki Inano, Yuka Sugimoto, Kohshi Ohishi

|Mar 04, 2026
Consensus on the use of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a modified Delphi survey.

Kazuya Shimoda, Katsuto Takenaka, Haruna Kitamura

|Feb 17, 2026
Clathrin-associated SCYL2 contributes to the activation of PI3K/AKT signaling and tumorigenesis through PTEN phosphorylation in adult T-cell leukemia/lymphoma.

Tomonaga Ichikawa, Shunsuke Shimosaki, Shingo Nakahata

|Nov 26, 2024
JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).

Naoto Takahashi, Katsuto Takenaka, Noriyoshi Iriyama

|Aug 07, 2024
Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial.

Kazuya Shimoda, Norio Komatsu, Itaru Matsumura

|Jul 01, 2024
Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b.

Kazuya Shimoda, Albert Qin, Norio Komatsu

Pageof 3

Frequent Collaborators

3 joint publications

Takuro Kameda

2 joint publications

Goro Sashida

2 joint publications

Atsushi Iwama

2 joint publications

Yasunori Kogure